{"authors": [["Andrade", "Patr\u00edcia", "P", "Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, University of Porto, Porto, Portugal."], ["Rodrigues", "Susana", "S", "Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, University of Porto, Porto, Portugal."], ["Rodrigues-Pinto", "Eduardo", "E", "Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, University of Porto, Porto, Portugal."], ["Gaspar", "Rui", "R", "Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, University of Porto, Porto, Portugal."], ["Lopes", "Joanne", "J", "Department of Pathology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, University of Porto, Porto, Portugal."], ["Lopes", "Susana", "S", "Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, University of Porto, Porto, Portugal."], ["Macedo", "Guilherme", "G", "Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, University of Porto, Porto, Portugal."]], "text": "Controlled attenuation parameter (CAP), measured by transient elastography, has been suggested as a noninvasive method for the detection and quantification of steatosis. We aimed to assess the accuracy of CAP to detect steatosis in patients with chronic liver disease (CLD) compared with liver histology and to evaluate factors that correlate with the CAP value.Patients with CLD who underwent liver biopsy and simultaneous CAP determination were consecutively enrolled. CAP was measured using the M probe of FibroScan\u00ae (Echosens, Paris, France). Histologically, steatosis was categorized as absent (S0: <5%), mild (S1: 5-33%), moderate (S2: 34-66%) and severe (S3: >66% of all hepatocytes).We analyzed 159 patients with CLD (61% men, mean age 47.9 \u00b1 12.9 years). We found a positive correlation between CAP and steatosis in histology (rs = 0.869, p < 0.001), arterial hypertension (rs = 0.222, p = 0.005), type 2 diabetes mellitus (rs = 0.279, p < 0.001), body mass index (BMI; rs = 0.533, p < 0.001), total cholesterol (rs = 0.442, p < 0.001), triglycerides (rs = 0.272, p = 0.001), and non-alcoholic fatty liver disease (NAFLD; rs = 0.588, p < 0.001). In the multivariate analysis, BMI >25 (odds ratio [OR] 48.4, 95% confidence interval [CI] 23.78-72.95, p < 0.001), serum total cholesterol (OR 3.803, 95% CI 2.203-13.889, p = 0.008), and NAFLD etiology (OR 40.8, 95% CI 15.01-66.66, p = 0.002) were independently associated with higher CAP values. We did not find any significant correlation between CAP and the grade of necroinflammatory activity (rs = 0.063, p = 0.808) or fibrosis (rs = 0.071, p = 0.713) in histology and with alanine aminotransferase (rs = 0.190, p = 0.356) or aspartate aminotransferase (rs = 0.117, p = 0.142). Optimal CAP cutoff values for detecting steatosis \u2265S1, \u2265S2, and \u2265S3 were 206.5, 232.5, and 282.5 dB/m, respectively. CAP performance was 0.822, 0.956, and 0.976 for diagnosing steatosis \u2265S1, \u2265S2, and \u2265S3, respectively.CAP had an excellent diagnostic accuracy for the detection of steatosis in diverse CLD patients. A CAP value cutoff of <282.5 dB/m excludes severe steatosis \u2265S3 with an accuracy of 98%.O Par\u00e2metro de Atenua\u00e7\u00e3o Controlada (CAP) medido por elastografia hep\u00e1tica tem sido sugerido como um m\u00e9todo n\u00e3o invasivo para dete\u00e7\u00e3o e quantifica\u00e7\u00e3o de esteatose. O objetivo deste estudo foi avaliar a acuidade do CAP na avalia\u00e7\u00e3o da esteatose hep\u00e1tica nos doentes com doen\u00e7a hep\u00e1tica cr\u00f3nica (DHC) comparativamente \u00e0 histologia e avaliar os fatores que se correlacionam com o valor de CAP.Inclu\u00eddos os doentes com DHC que realizaram simultaneamente bi\u00f3psia hep\u00e1tica e avalia\u00e7\u00e3o do CAP. Para avalia\u00e7\u00e3o do CAP foi utilizada a sonda M do Fibroscan\u00ae (Echosens, Paris, France). Na histologia, a esteatose foi categorizada em ausente (S0: <5%), ligeira (S1: 5\u201333%), moderada (S2: 34\u201366%) e grave (S3: >66% de hepat\u00f3citos).Foram analisados 159 doentes com DHC (61% homens; idade m\u00e9dia 47.9 \u00b1 12.9 anos). Verificou-se uma correla\u00e7\u00e3o positiva entre o CAP e esteatose na histologia (rs = 0.869, p < 0.001), hipertens\u00e3o arterial (rs = 0.222, p = 0.005), diabetes mellitus tipo 2 (rs = 0.279, p < 0.001), \u00edndice de massa corporal (rs = 0.533, p < 0.001), colesterol total (rs = 0.442, p < 0.001), triglicer\u00eddeos (rs = 0.272, p = 0.001) e NAFLD (rs = 0.588, p < 0.001). Na an\u00e1lise multivariada, IMC>25 mg/kg2 (odds ratio [OR] 48.4, IC 95%: 23.78\u201372.95, p < 0.001), o colesterol s\u00e9rico (OR 3.803, IC 95%: 2.203\u201313.889, p = 0.008) e etiologia NAFLD (OR 40.8, IC 95%: 15.01\u201366.66, p = 0.002) associaram-se de forma independente a valores de CAP mais elevados. O CAP n\u00e3o se correlacionou com o grau de atividade necroinflamat\u00f3ria (rs = 0.063, p = 0.808) ou de fibrose na histologia (rs = 0.071, p = 0.713) nem com o valor de ALT (rs = 0.190, p = 0.356) ou AST (rs = 0.117, p = 0.142). O melhor cutoff para diagn\u00f3stico de esteatose \u2265S1, \u2265S2 e \u2265S3 foi 206.5 dB/m, 232.5 dB/m e 282.5 dB/m, respetivamente. A acuidade do CAP para diagn\u00f3stico de esteatose \u2265S1, \u2265S2 e \u2265S3, CAP foi 0.822, 0.956 e 0.976, respetivamente.O CAP apresentou elevada acuidade diagn\u00f3stica na dete\u00e7\u00e3o de esteatose em doentes com doen\u00e7a hep\u00e1tica cr\u00f3nica. Um valor de CAP inferior a 282.5 dB/m exclui esteatose \u2265S3 com 98% de acuidade.", "id": "29255745", "date": "2016-12-23", "title": "Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.", "doi": "10.1159/000453364", "journal": ["GE Portuguese journal of gastroenterology", "GE Port J Gastroenterol"]}